OnCo
trialsTrialCompleted

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

A phase 3 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Radiomedix, Inc., completed.